Merck is carving out its own place in the evolving HIV treatment space with an FDA approval for its Idvynso, a combination ...
After prevailing in two kidney cancer trials in the refractory and early-stage settings, Merck & Co.’s blockbuster prospect ...
Pfizer’s chief strategist Andrew Baum, M.D., is leaving his post two years after pivoting from a career-long tenure as a ...
With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift ...
The era of off-label guesswork for patients living with the rare autoimmune disorder MOGAD may soon be over, as a phase 3 ...
Already approved to treat four rare diseases, AstraZeneca’s Ultomiris has shown its ability against another rare disorder, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results